engleski

Combination therapy with prescription omega-3-acid ethyl esters and statin improves non-HDL-C more effectively than statin alone

Non-HDL-C is an important parameter of cardiovascular risk but many patients do not achieve non-HDL-C target values by monotherapy with a statin. In this study, the effects of combined treatment with prescription omega-3 fatty acid ethyl esters plus escalating dosages (10, 20 and 40mg/day) of atorvastatin on non-HDL-C and other lipid parameters were investigated in a 20-week, multicenter, double-blind, placebo-controlled study of 245 patients with high non-HDL-C.

atoravastatin; combination therapy; dyslipidemia; omega-3 fatty acid; statin

nije evidentirano